Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis.

Iannello A, Rolla S, Maglione A, Ferrero G, Bardina V, Inaudi I, De Mercanti S, Novelli F, D'Antuono L, Cardaropoli S, Todros T, Turrini MV, Cordioli C, Puorro G, Marsili A, Lanzillo R, Brescia Morra V, Cordero F, De Bortoli M, Durelli L, Visconti A, Cutrupi S, Clerico M.

Front Immunol. 2019 Jan 8;9:3075. doi: 10.3389/fimmu.2018.03075. eCollection 2018.

2.

Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.

Lavorgna L, Esposito S, Lanzillo R, Sparaco M, Ippolito D, Cocco E, Fenu G, Borriello G, De Mercanti S, Frau J, Capuano R, Trojsi F, Rosa L, Clerico M, Laroni A, Morra VB, Tedeschi G, Bonavita S.

J Neurol. 2019 Jan 16. doi: 10.1007/s00415-019-09193-4. [Epub ahead of print]

PMID:
30649617
3.

Normative values of the Rao's Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education.

Falco F, Moccia M, Chiodi A, Carotenuto A, D'Amelio A, Rosa L, Piscopo K, Falco A, Costabile T, Lauro F, Brescia Morra V, Lanzillo R.

Neurol Sci. 2019 Jan 15. doi: 10.1007/s10072-019-3712-3. [Epub ahead of print]

PMID:
30645750
4.

Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin.

Lanzillo R, Moccia M, Russo CV, Carotenuto A, Nozzolillo A, Petruzzo M, Palladino R, Chataway J, Brescia Morra V.

Mult Scler Relat Disord. 2019 Jan 2;28:193-196. doi: 10.1016/j.msard.2018.12.042. [Epub ahead of print]

PMID:
30623857
5.

MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis.

Cocozza S, Pontillo G, Lanzillo R, Russo C, Petracca M, Di Stasi M, Paolella C, Vola EA, Criscuolo C, Moccia M, Lamberti A, Monti S, Brescia Morra V, Elefante A, Palma G, Tedeschi E, Brunetti A.

Neuroradiology. 2019 Feb;61(2):155-162. doi: 10.1007/s00234-018-02150-4. Epub 2019 Jan 8.

PMID:
30617409
6.

Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.

Pontillo G, Cocozza S, Lanzillo R, Russo C, Stasi MD, Paolella C, Vola EA, Criscuolo C, Borrelli P, Palma G, Tedeschi E, Morra VB, Elefante A, Brunetti A.

AJNR Am J Neuroradiol. 2019 Jan;40(1):99-106. doi: 10.3174/ajnr.A5915. Epub 2018 Dec 20.

PMID:
30573464
7.

Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment.

Megna R, Alfano B, Lanzillo R, Costabile T, Comerci M, Vacca G, Carotenuto A, Moccia M, Servillo G, Prinster A, Brescia Morra V, Quarantelli M.

J Neurol. 2019 Feb;266(2):361-368. doi: 10.1007/s00415-018-9139-6. Epub 2018 Nov 29.

PMID:
30498912
8.

Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.

Buonomo AR, Saccà F, Zappulo E, De Zottis F, Lanzillo R, Gentile I, Carotenuto A, Borgia G, Russo CV.

Mult Scler Relat Disord. 2019 Jan;27:44-45. doi: 10.1016/j.msard.2018.09.031. Epub 2018 Oct 2.

PMID:
30316174
9.

Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis.

Ugga L, Cocozza S, Pontillo G, Russo C, Brescia Morra V, Lanzillo R, Riccio E, Pisani A, Brunetti A.

Brain Behav. 2018 Nov;8(11):e01121. doi: 10.1002/brb3.1121. Epub 2018 Oct 2.

10.

Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis.

Carotenuto A, Costabile T, Moccia M, Falco F, Scala MR, Russo CV, Saccà F, De Rosa A, Lanzillo R, Brescia Morra V.

Mult Scler Relat Disord. 2019 Jan;27:1-6. doi: 10.1016/j.msard.2018.09.024. Epub 2018 Sep 22.

PMID:
30273697
11.

Integrated Cognitive and Neuromotor Rehabilitation in Multiple Sclerosis: A Pragmatic Study.

Barbarulo AM, Lus G, Signoriello E, Trojano L, Grossi D, Esposito M, Costabile T, Lanzillo R, Saccà F, Morra VB, Conchiglia G.

Front Behav Neurosci. 2018 Sep 5;12:196. doi: 10.3389/fnbeh.2018.00196. eCollection 2018.

12.

e-Health and multiple sclerosis: An update.

Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S.

Mult Scler. 2018 Nov;24(13):1657-1664. doi: 10.1177/1352458518799629. Epub 2018 Sep 19.

PMID:
30231004
13.

Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction.

Carotenuto A, Cocozza S, Quarantelli M, Arcara G, Lanzillo R, Brescia Morra V, Cerillo I, Tedeschi E, Orefice G, Bambini V, Brunetti A, Iodice R.

Brain Lang. 2018 Oct;185:47-53. doi: 10.1016/j.bandl.2018.08.003. Epub 2018 Aug 12.

PMID:
30110668
14.

Retinal vascular density in multiple sclerosis: a 1-year follow-up.

Lanzillo R, Cennamo G, Moccia M, Criscuolo C, Carotenuto A, Frattaruolo N, Sparnelli F, Melenzane A, Lamberti A, Servillo G, Tranfa F, De Crecchio G, Brescia Morra V.

Eur J Neurol. 2019 Jan;26(1):198-201. doi: 10.1111/ene.13770. Epub 2018 Sep 3.

PMID:
30102834
15.

Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis.

Lavorgna L, De Stefano M, Sparaco M, Moccia M, Abbadessa G, Montella P, Buonanno D, Esposito S, Clerico M, Cenci C, Trojsi F, Lanzillo R, Rosa L, Morra VB, Ippolito D, Maniscalco G, Bisecco A, Tedeschi G, Bonavita S.

Mult Scler Relat Disord. 2018 Oct;25:175-178. doi: 10.1016/j.msard.2018.07.046. Epub 2018 Jul 31.

PMID:
30096683
16.

Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?

Cocozza S, Pontillo G, Russo C, Russo CV, Costabile T, Pepe A, Tedeschi E, Lanzillo R, Brescia Morra V, Brunetti A, Inglese M, Petracca M.

J Neurol. 2018 Oct;265(10):2260-2266. doi: 10.1007/s00415-018-8985-6. Epub 2018 Jul 28.

PMID:
30056570
17.

Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP; ; On behalf of the iMUST Group.

Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390. [Epub ahead of print]

PMID:
30044207
18.

Clinical activity after fingolimod cessation: disease reactivation or rebound?

Frau J, Sormani MP, Signori A, Realmuto S, Baroncini D, Annovazzi P, Signoriello E, Maniscalco GT, La Gioia S, Cordioli C, Frigeni B, Rasia S, Fenu G, Grasso R, Sartori A, Lanzillo R, Stromillo ML, Rossi S, Forci B, Cocco E; i-MuST study group.

Eur J Neurol. 2018 Oct;25(10):1270-1275. doi: 10.1111/ene.13694. Epub 2018 Jul 10.

PMID:
29851435
19.

Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.

Lanzillo R, Moccia M, Criscuolo C, Cennamo G.

Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060. [Epub ahead of print] No abstract available.

PMID:
29587576
20.

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.

J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.

PMID:
29549468
21.

Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis.

Lavorgna L, Miele G, Petruzzo M, Lanzillo R, Bonavita S.

Mult Scler Relat Disord. 2018 Apr;21:108-109. doi: 10.1016/j.msard.2018.02.014. Epub 2018 Feb 12. No abstract available.

PMID:
29547779
22.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
23.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
24.

Cardiovascular profile improvement during Natalizumab treatment.

Moccia M, Albero R, Lanzillo R, Saccà F, De Rosa A, Russo CV, Carotenuto A, Palladino R, Brescia Morra V.

Metab Brain Dis. 2018 Jun;33(3):981-986. doi: 10.1007/s11011-017-0169-z. Epub 2017 Dec 18.

25.

Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration.

La Rocca C, Carbone F, De Rosa V, Colamatteo A, Galgani M, Perna F, Lanzillo R, Brescia Morra V, Orefice G, Cerillo I, Florio C, Maniscalco GT, Salvetti M, Centonze D, Uccelli A, Longobardi S, Visconti A, Matarese G.

Metabolism. 2017 Dec;77:39-46. doi: 10.1016/j.metabol.2017.08.011. Epub 2017 Sep 8.

26.

A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis.

Moccia M, Palladino R, Carotenuto A, Saccà F, Russo CV, Lanzillo R, Brescia Morra V.

Mult Scler Relat Disord. 2018 Jan;19:50-54. doi: 10.1016/j.msard.2017.11.006. Epub 2017 Nov 6.

PMID:
29128737
27.

Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.

Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group.

Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1.

PMID:
29093064
28.

Social Media and Multiple Sclerosis in the Posttruth Age.

Lavorgna L, Lanzillo R, Brescia Morra V, Abbadessa G, Tedeschi G, Bonavita S.

Interact J Med Res. 2017 Sep 27;6(2):e18. doi: 10.2196/ijmr.7879.

29.

Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.

Lanzillo R, Cennamo G, Criscuolo C, Carotenuto A, Velotti N, Sparnelli F, Cianflone A, Moccia M, Brescia Morra V.

Mult Scler. 2018 Nov;24(13):1706-1714. doi: 10.1177/1352458517729463. Epub 2017 Sep 21.

PMID:
28933233
30.

Cerebellar lobule atrophy and disability in progressive MS.

Cocozza S, Petracca M, Mormina E, Buyukturkoglu K, Podranski K, Heinig MM, Pontillo G, Russo C, Tedeschi E, Russo CV, Costabile T, Lanzillo R, Harel A, Klineova S, Miller A, Brunetti A, Morra VB, Lublin F, Inglese M.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1065-1072. doi: 10.1136/jnnp-2017-316448. Epub 2017 Aug 26.

PMID:
28844067
31.

A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.

Ghezzi A, Bianchi A, Baroncini D, Bertolotto A, Malucchi S, Bresciamorra V, Lanzillo R, Milani N, Martinelli V, Patti F, Chisari C, Rottoli M, Simone M, Paolicelli D, Visconti A; FUTURE Study Group.

Neurol Sci. 2017 Nov;38(11):1999-2005. doi: 10.1007/s10072-017-3091-6. Epub 2017 Aug 22.

PMID:
28831635
32.

Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a.

Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De Rosa V, Colamatteo A, Micillo T, De Luca Picione C, Saccà F, De Rosa A, Moccia M, Brescia Morra V, Matarese G.

Clin Immunol. 2017 Oct;183:249-253. doi: 10.1016/j.clim.2017.08.011. Epub 2017 Aug 18.

PMID:
28823971
33.

Health-Related Coping and Social Interaction in People with Multiple Sclerosis Supported by a Social Network: Pilot Study With a New Methodological Approach.

Lavorgna L, Russo A, De Stefano M, Lanzillo R, Esposito S, Moshtari F, Rullani F, Piscopo K, Buonanno D, Brescia Morra V, Gallo A, Tedeschi G, Bonavita S.

Interact J Med Res. 2017 Jul 14;6(2):e10. doi: 10.2196/ijmr.7402.

34.

Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study.

Pontillo G, Cocozza S, Lanzillo R, Borrelli P, De Rosa A, Brescia Morra V, Tedeschi E, Palma G.

Front Neurol. 2017 Jun 19;8:294. doi: 10.3389/fneur.2017.00294. eCollection 2017.

35.

CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.

Carotenuto A, Scalia G, Ausiello F, Moccia M, Russo CV, Saccà F, De Rosa A, Criscuolo C, Del Vecchio L, Brescia Morra V, Lanzillo R.

J Neuroimmunol. 2017 Aug 15;309:47-50. doi: 10.1016/j.jneuroim.2017.05.006. Epub 2017 May 12.

PMID:
28601287
36.

Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans.

Hayashi G, Jasoliya M, Sahdeo S, Saccà F, Pane C, Filla A, Marsili A, Puorro G, Lanzillo R, Brescia Morra V, Cortopassi G.

Hum Mol Genet. 2017 Aug 1;26(15):2864-2873. doi: 10.1093/hmg/ddx167.

37.

Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study.

Lavorgna L, Moccia M, Russo A, Palladino R, Riccio L, Lanzillo R, Brescia Morra V, Tedeschi G, Bonavita S.

Mult Scler Relat Disord. 2017 Apr;13:28-32. doi: 10.1016/j.msard.2017.02.001. Epub 2017 Feb 5.

38.

Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis.

Cocozza S, Olivo G, Riccio E, Russo C, Pontillo G, Ugga L, Migliaccio S, de Rosa D, Feriozzi S, Veroux M, Battaglia Y, Concolino D, Pieruzzi F, Tuttolomondo A, Caronia A, Russo CV, Lanzillo R, Brescia Morra V, Imbriaco M, Brunetti A, Tedeschi E, Pisani A.

Neuroradiology. 2017 Jun;59(6):563-570. doi: 10.1007/s00234-017-1829-8. Epub 2017 Apr 6.

PMID:
28386689
39.

What should we expect from multiple sclerosis therapy? Results of an integrated analysis of delayed-release dimethyl fumarate pivotal trials.

Lanzillo R.

Eur J Neurol. 2017 May;24(5):661-662. doi: 10.1111/ene.13283. Epub 2017 Mar 22. No abstract available.

PMID:
28332255
40.

Erratum: Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae.

Walvoort MT, Testa C, Eilam R, Aharoni R, Nuti F, Rossi G, Real-Fernandez F, Lanzillo R, Brescia Morra V, Lolli F, Rovero P, Imperiali B, Papini AM.

Sci Rep. 2017 Mar 22;7:44969. doi: 10.1038/srep44969. No abstract available.

41.

The importance of being persistent to multiple sclerosis treatments.

Moccia M, Lanzillo R, Cerullo G, De Rosa A, Brescia Morra V.

J Clin Neurosci. 2017 Jun;40:198-199. doi: 10.1016/j.jocn.2017.02.004. Epub 2017 Feb 27. No abstract available.

PMID:
28246007
42.

Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.

Moccia M, Palladino R, Lanzillo R, Carotenuto A, Russo CV, Triassi M, Brescia Morra V.

PLoS One. 2017 Jan 5;12(1):e0169489. doi: 10.1371/journal.pone.0169489. eCollection 2017.

43.

Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae.

Walvoort MT, Testa C, Eilam R, Aharoni R, Nuti F, Rossi G, Real-Fernandez F, Lanzillo R, Brescia Morra V, Lolli F, Rovero P, Imperiali B, Papini AM.

Sci Rep. 2016 Dec 23;6:39430. doi: 10.1038/srep39430. Erratum in: Sci Rep. 2017 Mar 22;7:44969.

44.

Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon β-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis.

Lanzillo R, Di Somma C, Quarantelli M, Carotenuto A, Pivonello C, Moccia M, Cianflone A, Marsili A, Puorro G, Saccà F, Russo CV, De Luca Picione C, Ausiello F, Colao A, Brescia Morra V.

Eur J Neurol. 2017 Feb;24(2):446-449. doi: 10.1111/ene.13207. Epub 2016 Dec 16.

PMID:
27982500
45.

A longitudinal real-life comparison study of natalizumab and fingolimod.

Lanzillo R, Carotenuto A, Moccia M, Saccà F, Russo CV, Massarelli M, De Rosa A, Brescia Morra V.

Acta Neurol Scand. 2017 Sep;136(3):217-222. doi: 10.1111/ane.12718. Epub 2016 Dec 15.

PMID:
27976804
46.

Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience.

Rainone N, Chiodi A, Lanzillo R, Magri V, Napolitano A, Morra VB, Valerio P, Freda MF.

Qual Life Res. 2017 Mar;26(3):727-736. doi: 10.1007/s11136-016-1466-4. Epub 2016 Dec 7.

PMID:
27928696
47.

Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.

Moccia M, Palladino R, Carotenuto A, Russo CV, Triassi M, Lanzillo R, Brescia Morra V.

Mult Scler Relat Disord. 2016 Nov;10:90-96. doi: 10.1016/j.msard.2016.09.011. Epub 2016 Sep 28.

PMID:
27919507
48.

The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.

Saccà F, Costabile T, Carotenuto A, Lanzillo R, Moccia M, Pane C, Russo CV, Barbarulo AM, Casertano S, Rossi F, Signoriello E, Lus G, Brescia Morra V.

Mult Scler. 2017 Aug;23(9):1289-1296. doi: 10.1177/1352458516677592. Epub 2016 Nov 3.

PMID:
27811338
49.

Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression.

Moccia M, Quarantelli M, Lanzillo R, Cocozza S, Carotenuto A, Carotenuto B, Alfano B, Prinster A, Triassi M, Nardone A, Palladino R, Brunetti A, Brescia Morra V.

Eur J Neurol. 2017 Jan;24(1):195-204. doi: 10.1111/ene.13183. Epub 2016 Nov 1.

PMID:
27801535
50.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Lanzillo R, Moccia M, Laplaud DA, Foucher Y.

Neurology. 2016 Sep 6;87(10):1066. doi: 10.1212/01.wnl.0000497026.62085.8d. No abstract available.

PMID:
27597557

Supplemental Content

Loading ...
Support Center